Nexstim Plc announced that it has received an order and delivered two new NBS 6 systems to a private clinic customer in the United States. The customer is an experienced Nexstim system user that is now upgrading its existing systems at two clinic locations. Nexstim launched NBS 6, a new generation nTMS system, in 2023.

The NBS 6 is cleared by the FDA for the treatment of Major Depressive Disorder (MDD) in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode.